Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983135 | 0.89 | PPARG (0.46) | PPARGPPARACYP2C9KCNH2TP53 | |
| SCHEMBL3987380 | 0.85 | FFAR1 (0.49) | PPARGPPARATP53MAPTFFAR1 | |
| SCHEMBL3984825 | 0.83 | FFAR1 (0.48) | PPARGPPARATP53MAPTFFAR1 | |
| SCHEMBL3980527 | 0.82 | FFAR1 (0.47) | PPARGPPARATP53MAPTFFAR1 | |
| SCHEMBL3986322 | 0.81 | FFAR1 (0.48) | PPARGPPARAMAPTFFAR1 | |
| SCHEMBL3983218 | 0.80 | FFAR1 (0.45) | PPARGPPARATP53MAPTFFAR1 | |
| SCHEMBL3286564 | 0.80 | TP53 (0.54) | PPARGPPARACYP2C9KCNH2TP53 | |
| SCHEMBL27636270 | 0.78 | FFAR1 (0.49) | PPARGPPARATP53MAPTFFAR1 | |
| SCHEMBL3985839 | 0.78 | FFAR1 (0.53) | PPARGPPARATP53MAPTFFAR1 | |
| SCHEMBL3982907 | 0.77 | FFAR1 (0.51) | PPARGPPARATP53MAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | claimed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | claimed |
| EP-1646628-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Novartis AG (CH) | 2006-04-19 | — | — | EP | claimed |
| WO-2005005421-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | claimed |
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | disclosed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1646628-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Novartis AG (CH) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005421-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885CYP2C9 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.